Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade

What Was Tested

This clinical trial paper looks at Goserelin in the context of immune system (general).

Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells), quantitative PCR to assess T-cell receptor excision circle levels (as a correlate of thymus function), CDR3 length analysis to determine the variability of the TCR repertoire, and in vitro assays to determine functional T cell responses.

Who Took Part

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Goserelin study would be practical.

The timeline in the abstract includes 3 months.

This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Hormonal, Combined Modality Therapy, Flow Cytometry, Goserelin, Graft vs Host Disease, Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation.

What This Means in Plain Language

The paper is a pilot study of Goserelin in people with immune system (general) over 3 months.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Clinical cancer research : an official journal of the American Association for Cancer Research), a journal based in United States.

More context: the Goserelin compound page, Immune system (general) research.